S. 3019: No Big Blockbuster Bailouts Act

This bill, known as the No Big Blockbuster Bailouts Act, proposes amendments to existing legislation regarding drugs used for rare diseases, referred to as orphan drugs, within the context of the Medicare Drug Price Negotiation Program. The main provisions of the bill are as follows:

Purpose of the Bill

The bill aims to modify how orphan drugs are treated under Medicare price negotiations, particularly focusing on the financial thresholds involved in the pricing of these drugs.

Key Amendments

• The bill alters specific language in Section 1192(e) of the Social Security Act, particularly concerning the pricing limits applied to orphan drugs.
• In one notable change, the threshold for annual revenue that classifies a drug as an orphan drug will increase from $200 million to $400 million. This means that any orphan drug that generates revenue below this higher threshold will be treated differently in terms of price negotiations with Medicare.
• The bill also modifies other procedural and structural elements within the pricing regulations to account for these changes.

Implementation Timeline

The changes brought about by this bill would not take effect immediately. Specifically, the new pricing parameters would apply to drug price negotiations starting from initial price applicability years beginning on or after January 1, 2028.

Conclusion of Bill Provisions

The adjustments proposed by this bill could affect how orphan drugs are priced in the Medicare system, ultimately influencing affordability and market strategies for those developing treatments for rare diseases.

Relevant Companies

• BIIB (Biogen Inc.): As a leader in treatments for neurological conditions, Biogen may see impacts on its orphan drug pricing, specifically for its therapies targeting rare diseases.
• AMGN (Amgen Inc.): Known for its focus on biologic therapies, Amgen could be affected by changes in the pricing structure of its orphan drugs, potentially altering its market strategy.
• REGN (Regeneron Pharmaceuticals): Regeneron’s portfolio includes orphan drugs that could be impacted by the increased revenue thresholds defined in this bill, which might affect its pricing negotiations with Medicare.